Susquehanna International Group, LLP Inozyme Pharma, Inc. Call Options Transaction History

Susquehanna International Group, LLP

  • $560 Billion
  • Q3 2024

Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 15, 2024
BUY
$4.33 - $7.31 $69,713 - $117,691
16,100 New
16,100 $71,000
Q4 2023

Feb 14, 2024
SELL
$2.71 - $4.5 $415,714 - $690,300
-153,400 Reduced 88.88%
19,200 $81,000
Q3 2023

Nov 14, 2023
BUY
$4.09 - $7.0 $646,220 - $1.11 Million
158,000 Added 1082.19%
172,600 $724,000
Q2 2023

Aug 11, 2023
SELL
$4.93 - $6.74 $24,157 - $33,026
-4,900 Reduced 25.13%
14,600 $81,000
Q1 2023

May 16, 2023
BUY
$1.3 - $5.73 $25,350 - $111,735
19,500 New
19,500 $111,000

Others Institutions Holding INZY

# of Institutions
90
Shares Held
53M
Call Options Held
3.7K
Put Options Held
5.8K
View Full List

About Inozyme Pharma, Inc.

INZY Quotes by TradingView
  • Ticker INZY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,145,700
  • Market Cap $116M
  • Description
  • Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...
More about INZY
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email